Source: Google NewsPublished on 2022-02-13
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Monthly Research Review – December 2021 December 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Updated Insight Parkinson's Disease Market Future Trends, Scope, Top Players 2016 to 2028 | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun Pharma… – Political Beef - Political Beef April 18, 2022 Updated Insight Parkinson's Disease Market Future Trends, Scope, Top Players 2016 to 2028 | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun Pharma… – Political Beef Political Beef
- Global Parkinson's Disease Market Report, Growth Insight, Deep Research & Segment Analysis | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun Pharm… – The Daily Vale - The Daily Vale May 25, 2022 Global Parkinson's Disease Market Report, Growth Insight, Deep Research & Segment Analysis | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun Pharm… – The Daily Vale The Daily Vale
- Parkinson's Disease Market Upcoming Trends, Segmented by Type, Application, End-User and Region | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun … – ChattTenn Sports - ChattTenn Sports March 27, 2022 Parkinson's Disease Market Upcoming Trends, Segmented by Type, Application, End-User and Region | Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, Merck, Sun … – ChattTenn Sports ChattTenn Sports
- Monthly Research Review – June 2021 June 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during June 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
- Global Parkinson's Disease Market 2027 Scope And Opportunities Analysis In Pandemic Crisis during Covid-19: Teva, Novartis, GSK, AbbVie, Merck, Boehringer Ingelheim, Amneal + Impax, Lundbeck, Sun Pharma, Wockhardt, UCB, Bausch Health, Acadia… January 19, 2021 Global Parkinson's Disease Market 2027 Scope And Opportunities Analysis In Pandemic Crisis during Covid-19: Teva, Novartis, GSK, AbbVie, Merck, Boehringer Ingelheim, Amneal + Impax, Lundbeck, Sun Pharma, Wockhardt, UCB, Bausch Health, Acadia NeighborWebSJ
- Parkinson's Disease Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, ... - The Market Writeuo - The Market Writeuo August 11, 2021 Parkinson's Disease Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, ... - The Market Writeuo The Market Writeuo
- ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
- Mo better for TEVA with Modag? October 27, 2021 # # # # This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b. Anle138b is a small molecule inhibitor of the believed to be toxic forms of…
- Parkinson's Disease Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, … – Energy Siren - Energy Siren November 13, 2021 Parkinson's Disease Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Teva, Lundbeck, AbbVie, Novartis, Amneal + Impax, GSK, Wockhardt, Boehringer Ingelheim, … – Energy Siren Energy Siren
- Parkinson's Disease Treatment Market Size, Share, Development by 2025 Top Key players like Teva, Novartis AG, GSK, AbbVie , Merck , Boehringer Ingelheim, Impax Laboratories , Lundbeck, UCB, Valeant Pharmaceuticals, Acadia , Sun Pharma,… August 5, 2019 Parkinson's Disease Treatment Market Size, Share, Development by 2025 Top Key players like Teva, Novartis AG, GSK, AbbVie , Merck , Boehringer Ingelheim, Impax Laboratories , Lundbeck, UCB, Valeant Pharmaceuticals, Acadia , Sun Pharma, Wockhardt Market Report GazetteMarket Report Gazette provides latest industry trending news, news *service*, IT & Technology news helps businesses connect with their target audiences in ...
- Global Parkinson's Disease Treatments Market 2019-2026 | Top key players are GSK ,Merck ,Novartis ,Teva ,Boehringer Ingelheim ,Impax ,Abbvie ,Valeant Pharmaceuticals ,Lundbeck ,Sun Pharma ,Wockhardt ,Acadia ,UCB - Financial Newspaper September 5, 2019 Global Parkinson's Disease Treatments Market 2019-2026 | Top key players are GSK ,Merck ,Novartis ,Teva ,Boehringer Ingelheim ,Impax ,Abbvie ,Valeant Pharmaceuticals ,Lundbeck ,Sun Pharma ,Wockhardt ,Acadia ,UCB Financial NewspaperGlobal Parkinson's Disease Treatments Market Professional Survey Report 2019. Parkinson's Disease Treatments Market 2019 Global Industry research report ...
- Updated Insight Parkinson's Disease Treatment Market Future Trends, Scope, Top Players 2016 to 2028 | GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun P… – ManufactureLink - ManufactureLink May 9, 2022 Updated Insight Parkinson's Disease Treatment Market Future Trends, Scope, Top Players 2016 to 2028 | GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun P… – ManufactureLink ManufactureLink
- Monthly Research Review – August 2021 August 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Forget Special K, maybe focus on LysoK February 20, 2021 # # # # Over the last 20 years, researchers have identified a number of genetic variations that can confer an increased risk of developing Parkinson’s. Tiny alterations in regions of DNA (called genes) – which provide the instructions for making a protein – can increase one’s chances of Parkinson’s. A better understanding of the biological pathways associated with these…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Parkinson's Disease Treatment Market Size, Share and Trends 2022-2028, Forecast Key Players | GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun Pharmaceu… – Materials Handling - Materials Handling February 24, 2022 Parkinson's Disease Treatment Market Size, Share and Trends 2022-2028, Forecast Key Players | GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun Pharmaceu… – Materials Handling Materials Handling
- Parkinson's Disease Treatment Market 2020 Global analysis, opportunities and forecast to 2027 | By Top Leading Vendors like GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun Pharmaceutical… January 5, 2021 Parkinson's Disease Treatment Market 2020 Global analysis, opportunities and forecast to 2027 | By Top Leading Vendors like GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health, Lundbeck, Sun Pharmaceutical Industries, Wockhardt, Acadia Pharmaceuticals, UCB, and More? Factory Gate